What is the current market size and future outlook for the personalized cell therapy market?
The personalized cell therapy market size has grown exponentially in recent years. It will grow from $17.11 billion in 2024 to $21 billion in 2025 at a compound annual growth rate (CAGR) of 22.8%. The growth in the historic period can be attributed to increasing awareness of personalized medicine, increasing healthcare spending, increasing government initiatives, increasing funding for clinical research, rise in neurological disorders.
The personalized cell therapy market size is expected to see exponential growth in the next few years. It will grow to $47.14 billion in 2029 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to rising clinical trials, rising incidence of chronic illnesses, growing geriatric population, rising prevalence of cancer, and increasing adoption of regenerative medicines. Major trends in the forecast period include technological advancements, integration of AI, personalized vaccines, bioinformatics, and microfluidic technologies.
Get Your Free Sample of The Global Personalized Cell Therapy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19137&type=smp
How has the personalized cell therapy market evolved, and what factors have shaped its growth?
The rise in neurological disorders is expected to drive the growth of the personalized cell therapy market going forward. Neurological disorders are a group of conditions affecting the brain, spinal cord, and nerves, leading to symptoms such as impaired motor function, cognitive deficits, and sensory disturbances. Neurological disorders are occurring due to an aging population, environmental stressors, and lifestyle changes contributing to higher incidences of neurodegenerative diseases. Personalized cell therapy is required for neurological disorders as it offers tailored treatments that target specific patient needs, potentially restoring damaged neural tissue and improving outcomes in complex, individualized conditions. For instance, in December 2022, according to the Parkinson Foundation, a US-based government organization, the yearly incidence of Parkinson’s disease (PD) among older persons is 50% greater than the existing estimate of 60,000 cases. Additionally, 1.2 million more Americans are predicted to have Parkinson’s disease by 2030. Therefore, the rise in neurological disorders is driving the growth of the personalized cell therapy market.
What are the major segments of the personalized cell therapy market?
The personalized cell therapymarket covered in this report is segmented –
1) By Cell Type: Lymphocytes, Mesenchymal Stem Cell, Hematopoietic Stem Cell, Other Cell Type
2) By Technique: Platelet Transfusions, Bone Marrow Transplantation, Packed Red Cell Transfusions, Organ Transplantation
3) By Application: Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, Cancer, Other Applications
4) By End-User: Hospital, Homecare, Specialty Clinics, Other End-User
Subsegments:
1) By Lymphocytes: T Cells, Natural Killer (NK) Cells, Regulatory T Cells
2) By Mesenchymal Stem Cells (MSCs): Bone Marrow-Derived MSCs, Adipose Tissue-Derived MSCs, Umbilical Cord-Derived MSCs
3) By Hematopoietic Stem Cells: Autologous Hematopoietic Stem Cells, Allogeneic Hematopoietic Stem Cells
4) By Other Cell Types: Dendritic Cells, Fibroblasts, Endothelial Cells
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/personalized-cell-therapy-global-market-report
Which companies dominate the personalized cell therapy market?
Major companies operating in the personalized cell therapy marker are AbbVie Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Cipla Limited, Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Nkarta Therapeutics Inc., Intellia Therapeutics Inc., Tessa Therapeutics Pte Ltd., Atara Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences Inc., Editas Medicine Inc., Cellectis S.A., Gracell Biotechnologies Inc., Mesoblast Limited, Fate Therapeutics Inc., Athersys Inc., Bellicum Pharmaceuticals Inc., Celyad Oncology SA, Century Therapeutics Inc., Gamida Cell Ltd., CRISPR Therapeutics AG, Allogene Therapeutics Inc.
How will evolving trends contribute to the growth of the personalized cell therapy market?
Major companies operating in the personalized cell therapy market are focused on forming strategic partnerships to accelerate the development and commercialization of innovative therapies. These collaborations help companies pool resources, expertise, and technologies to enhance research and development capabilities, streamline clinical trials, and navigate regulatory pathways more efficiently. For instance, in October 2022, Century Therapeutics Inc., a US-based biotechnology company, partnered with Bristol Myers Squibb (BMS), a US-based biopharmaceutical company, to develop and commercialize allogeneic cell therapies. This collaboration uses Century’s innovative induced pluripotent stem cell (iPSC) technology to create engineered natural killer (NK) and T cell therapies to treat hematologic malignancies and solid tumors. The agreement encompasses the development of up to four distinct cell therapy programs, with the initial focus on two specific areas: acute myeloid leukemia (AML) and multiple myeloma. These programs will utilize engineered NK cells or gamma delta T cells derived from iPSCs.
What are the key regional dynamics of the personalized cell therapy market, and which region leads in market share?
North America was the largest region in the personalized cell therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cell therapy marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Personalized Cell Therapy Market Report 2025 Offer?
The personalized cell therapy market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Personalized cell therapy refers to a type of medical treatment where a patient’s own cells, or cells that are specifically tailored to them, are used to treat a disease or condition. This therapy is customized to the individual’s unique biological profile, often involving the modification or manipulation of cells to enhance their therapeutic potential. The key advantage of personalized cell therapy is that it minimizes the risk of rejection and adverse reactions as the therapy is designed to be compatible with the patient’s own body.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19137
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
